{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T08:26:34Z","timestamp":1785486394666,"version":"3.56.0"},"reference-count":25,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2022,9,25]],"date-time":"2022-09-25T00:00:00Z","timestamp":1664064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Japan Society for the Promotion of Science (JSPS) KAKENHI","award":["20K18892"],"award-info":[{"award-number":["20K18892"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJERPH"],"abstract":"<jats:p>The National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB) Open Data Japan is helpful for attaining simple and comprehensive understanding of medical care in Japan. Herein, we investigated the transition of anti-HIV-drug use in Japan over a 4-year period from fiscal year (FY) 2016 to FY 2019 using data on anti-HIV drugs that were extracted from the 3rd, 4th, 5th, and 6th NDB Open Data Japan. Then, the data were stratified by mechanism of action, single-tablet regimen (STR) or non-STR, age groups, and sex and analyzed. Throughout the study period, the prescription volume for tenofovir alafenamide fumarate as the backbone drug and integrase strand transfer inhibitors as the anchor drug increased. In FY 2019, STRs constituted approximately 44% of the total combination antiretroviral therapy regimens, 1.6 times higher than that in FY 2016 (27%). With the advent of newer drugs and regimens, the differences in anti-HIV drugs prescribed to patients of different ages and sex gradually diminished; however, differences were unremarkable in the first period, especially between sexes. The NDB Open Data Japan made it relatively easy to evaluate recent trends in anti-HIV prescription in Japan, indicating its usefulness for continuous surveys in this field.<\/jats:p>","DOI":"10.3390\/ijerph191912130","type":"journal-article","created":{"date-parts":[[2022,9,25]],"date-time":"2022-09-25T23:13:27Z","timestamp":1664147607000},"page":"12130","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Understanding the Actual Use of Anti-HIV Drugs in Japan from 2016 to 2019: Demonstrating Epidemiological Relevance of NDB Open Data Japan for Understanding Japanese Medical Care"],"prefix":"10.3390","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7702-2035","authenticated-orcid":false,"given":"Hiroyuki","family":"Tanaka","sequence":"first","affiliation":[{"name":"Department of Practical Pharmacy, Faculty of Pharmaceutical Sciences, Toho University, 2-2-1 Miyama, Funabashi, Chiba 274-8510, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0346-7565","authenticated-orcid":false,"given":"Toshihisa","family":"Onoda","sequence":"additional","affiliation":[{"name":"Department of Practical Pharmacy, Faculty of Pharmaceutical Sciences, Toho University, 2-2-1 Miyama, Funabashi, Chiba 274-8510, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Ishii","sequence":"additional","affiliation":[{"name":"Department of Practical Pharmacy, Faculty of Pharmaceutical Sciences, Toho University, 2-2-1 Miyama, Funabashi, Chiba 274-8510, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,25]]},"reference":[{"key":"ref_1","unstructured":"Department of Health and Human Services (2022, July 20). Panel on Antiretroviral Guidelines for Adults and Adolescents, Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV, Available online: https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/guidelines\/documents\/adult-adolescent-arv\/guidelines-adult-adolescent-arv.pdf."},{"key":"ref_2","unstructured":"Ministry of Health, Labour and Welfare (2022, July 20). The Guidelines for the Treatment of HIV Infection, March 2022 Version. (In Japanese)."},{"key":"ref_3","first-page":"316","article-title":"Evaluation of the efficacy and safety of changes in antiretroviral regimens for HIV-infected patients","volume":"17","author":"Tanaka","year":"2014","journal-title":"J. Pharm. Sci."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1128\/CMR.00102-15","article-title":"Approved antiviral drugs over the past 50 years","volume":"29","author":"Li","year":"2016","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/QCO.0b013e32835ba6b1","article-title":"Life expectancy living with HIV: Recent estimates and future implications","volume":"26","author":"Nakagawa","year":"2013","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/hiv.13206","article-title":"Comorbidities and co-medications among 28,089 people living with HIV: A nationwide cohort study from 2009 to 2019 in Japan","volume":"23","author":"Naito","year":"2022","journal-title":"HIV Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.idc.2014.06.001","article-title":"Antiretroviral therapy: Current drugs","volume":"28","author":"Pau","year":"2014","journal-title":"Infect. Dis. Clin. North Am."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"ofz051","DOI":"10.1093\/ofid\/ofz051","article-title":"Risk and cost associated with drug-drug interactions among aging HIV patients receiving combined antiretroviral therapy in France","volume":"6","author":"Demessine","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1038\/s41598-022-05816-5","article-title":"Analysis of antiretroviral therapy switch rate and switching pattern for people living with HIV from a national database in Japan","volume":"12","author":"Naito","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_10","unstructured":"Ministry of Health, Labour and Welfare (2022, July 20). The 6th NDB Open Data Commentary. (Abstract in English)."},{"key":"ref_11","first-page":"173","article-title":"Investigation of prescription pattern of antiretroviral using the national database of health insurance claims specific health checkups of Japan open data","volume":"21","author":"Tanaka","year":"2019","journal-title":"J. AIDS Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"20237","DOI":"10.1038\/s41598-019-56534-4","article-title":"Comorbidity status in hospitalized elderly in Japan: Analysis from National Database of Health Insurance Claims and Specific Health Checkups","volume":"9","author":"Nojiri","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1111\/1756-185X.13974","article-title":"Prevalence of patients with rheumatoid arthritis and age-stratified trends in clinical characteristics and treatment, based on the National Database of Health Insurance Claims and Specific Health Checkups of Japan","volume":"23","author":"Nakajima","year":"2020","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_14","first-page":"132","article-title":"Adjusted for optimal Truvada\u00ae dosage by Tenofovir therapeutic drug monitoring\u2014Two cases of HIV-infected patients who were undergoing hemodialysis","volume":"20","author":"Tsukiji","year":"2018","journal-title":"J. AIDS Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"384","DOI":"10.35772\/ghm.2020.01065","article-title":"Nucleos(t)ide reverse transcriptase inhibitor-sparing regimens in the era of standard 3-drug combination therapies for HIV-1 infection","volume":"2","author":"Uchitsubo","year":"2020","journal-title":"Glob. Health Med."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Iwamoto, A., Taira, R., Yokomaku, Y., Koibuchi, T., Rahman, M., Izumi, Y., and Tadokoro, K. (2017). The HIV care cascade: Japanese perspectives. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0174360"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"S792","DOI":"10.1093\/infdis\/jix135","article-title":"Tenofovir Alafenamide Fumarate: A new Tenofovir prodrug for the treatment of chronic Hepatitis B infection","volume":"216","author":"Buti","year":"2017","journal-title":"J. Infect. Dis."},{"key":"ref_18","first-page":"141","article-title":"Tolerability of current antiretroviral single-tablet regimens","volume":"20","author":"Domingo","year":"2018","journal-title":"AIDS Rev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12981-020-00268-1","article-title":"Real-world adherence and persistence for newly-prescribed HIV treatment: Single versus multiple tablet regimen comparison among US medicaid beneficiaries","volume":"17","author":"Cohen","year":"2020","journal-title":"AIDS Res. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Cotte, L., Ferry, T., Pugliese, P., Valantin, M.A., Allavena, C., Cabi\u00e9, A., Poizot-Martin, I., Rey, D., Duvivier, C., and Cheret, A. (2017). Effectiveness and tolerance of single tablet versus once daily multiple tablet regimens as first-line antiretroviral therapy\u2014Results from a large french multicenter cohort study. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0170661"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s11908-019-0691-8","article-title":"Simplifying ARV therapy in the setting of resistance","volume":"21","author":"Pandit","year":"2019","journal-title":"Curr. Infect. Dis. Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1089\/aid.2013.0069","article-title":"Short communication: Aging not gender is associated with high atazanavir plasma concentrations in Asian HIV-infected patients","volume":"29","author":"Avihingsanon","year":"2013","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/QCO.0000000000000033","article-title":"Optimizing antiretroviral therapy for women living with HIV","volume":"27","author":"Greig","year":"2014","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.phrs.2008.07.007","article-title":"Gender differences in the treatment of HIV infection","volume":"58","author":"Floridia","year":"2008","journal-title":"Pharmacol. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1093\/cid\/ciz684","article-title":"Analysis of pharmacovigilance databases for dolutegravir safety in pregnancy","volume":"70","author":"Pozniak","year":"2020","journal-title":"Clin. Infect. Dis."}],"container-title":["International Journal of Environmental Research and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1660-4601\/19\/19\/12130\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:39:17Z","timestamp":1760143157000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1660-4601\/19\/19\/12130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,25]]},"references-count":25,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["ijerph191912130"],"URL":"https:\/\/doi.org\/10.3390\/ijerph191912130","relation":{},"ISSN":["1660-4601"],"issn-type":[{"value":"1660-4601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,25]]}}}